clinical trial · NCT04159610
Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis
Dr. August Wolff GmbH & Co. KG Arzneimittel·phase2·withdrawn
Primary Axillary HyperhidrosisWO3970Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
brief summary
The aim of this study is to investigate the safety, tolerability and efficacy of 1% GPB Cream compared to Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use under maximum use conditions.
started
Dec 1, 2019
primary completion
Oct 1, 2020
completion
Oct 1, 2020
last updated
Dec 24, 2024
official title
A Randomized, Open-Label, Multiple Dose, Two-Period Crossover Study Evaluating Maximum Use 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% in Men and Women with Primary Axillary Hyperhidrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol